Skip to content

Trial Summary

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).



ACTRN/NCT /ethics:


Scientific title:

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Sponsor / Cooperative group:

Merck Sharp & Dohme LLC

Trial & Patient Characteristics

Cancer TypeCarcinoma, Non-Small-Cell Lung
Trial TypeTreatment
PhasePhase III
Age Range18 Years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-02-06
Anticipated End Date2028-08-23

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penta
Phone08 8359 2565
Principal InvestigatorRohit Joshi
Recruitment StatusRecruiting